Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

AstraZeneca logo

AstraZeneca

Status and phase

Terminated
Phase 2

Conditions

Metastases, Neoplasm
Colorectal Neoplasms

Treatments

Drug: Placebo
Drug: leucovorin
Drug: 5-fluorouracil
Drug: ZD6126
Drug: oxaliplatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00065117
6126IL/00007
D2820C00007

Details and patient eligibility

About

The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Metastatic colorectal carcinoma
  • Suitable for first-line treatment of metastatic disease

Exclusion criteria

  • Peripheral neuropathy greater than Grade 1
  • Adjuvant therapy within 6 months prior to study treatment
  • Prior oxaliplatin
  • Prior pelvic or whole abdomen radiation
  • Any history of coronary angioplasty or history of myocardial infarction

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems